← Back to Search

Dexmedetomidine for Anesthetic Sparing (Dexmed-PRS Trial)

Phase 4
Waitlist Available
Led By Simon Whyte, MBBS, FRCA
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30min post-procedure
Awards & highlights

Dexmed-PRS Trial Summary

This trial will test whether dexmedetomidine can reduce the amount of propofol and remifentanil needed for dental procedures, compared to a control group.

Dexmed-PRS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30min post-procedure
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30min post-procedure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Propofol and remifentanil infusion rate reduction
Propofol and remifentanil sparing
Secondary outcome measures
PACU pain scores
PACU sedation

Side effects data

From 2020 Phase 4 trial • 798 Patients • NCT02004613
57%
Clinically important hypotension
9%
Clinically important bradycardia
1%
infection
1%
stroke
1%
Atelectasis
1%
Hemorrhage
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Dexmedetomidine

Dexmed-PRS Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Dexmedetomidine 1.00 mcg/kgExperimental Treatment1 Intervention
1.00 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
Group II: Dexmedetomidine 0.50 mcg/kgExperimental Treatment1 Intervention
0.50 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
Group III: Dexmedetomidine 0.25 mcg/kgExperimental Treatment1 Intervention
0.25 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
Group IV: Saline bolusPlacebo Group1 Intervention
10mL normal saline solution administered intravenously over 60 seconds starting after intubation.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dexmedetomidine
FDA approved

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,418 Previous Clinical Trials
2,467,030 Total Patients Enrolled
Simon Whyte, MBBS, FRCAPrincipal InvestigatorBC Children's Hospital, Department of Anesthesia
2 Previous Clinical Trials
424 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
The Effects of Dexmedetomidine on Intravenous Anesthetic Requirements for Children Undergoing Dental Procedures
Simon Whyte 2018. "The Effects of Dexmedetomidine on Intravenous Anesthetic Requirements for Children Undergoing Dental Procedures". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03422978.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top